首页> 外文期刊>Journal of Pain Research >Acute Cytokine Response During Breast Cancer Surgery: Potential Role of Dexamethasone and Lidocaine and Relationship with Postoperative Pain and Complications – Analysis of Three Pooled Pilot Randomized Controlled Trials
【24h】

Acute Cytokine Response During Breast Cancer Surgery: Potential Role of Dexamethasone and Lidocaine and Relationship with Postoperative Pain and Complications – Analysis of Three Pooled Pilot Randomized Controlled Trials

机译:乳腺癌手术期间的急性细胞因子反应:地塞米松和利多卡因的潜在作用以及与术后疼痛和并发症的关系 - 三个合并试点随机对照试验分析

获取原文
           

摘要

Purpose: An imbalance in perioperative cytokine response may cause acute pain and postoperative complications. Anesthetic drugs modulate this cytokine response, but their role in non-major breast cancer surgery is unclear. In an exploratory study, we investigated whether intravenous lidocaine and dexamethasone could modulate the cytokine response into an anti-inflammatory direction. We also evaluated interrelationships between cytokine levels, pain scores and postoperative complications. Our goal is to develop multimodal analgesia regimens optimizing outcome after breast cancer surgery. Patients and Methods: Forty-eight patients undergoing a lumpectomy were randomly assigned to placebo or lidocaine (1.5 mg?kgsup? 1/sup followed by 2 mg?kgsup? 1/sup?hoursup? 1/sup) supplemented by dexamethasone zero, 4 or 8 mg, yielding six groups of eight patients. Interleukin (IL)-1β, IL-1Ra, IL-6, IL-10 levels and pain scores were measured at baseline and four hours postoperatively. We assessed postoperative complications occurring within 30 days. We noted persistent pain and infections as potential immune-related complications (PIRC). We used multiple regression to disentangle the effects of the individual study drugs (given by their partial regression coefficients (b)). Odds ratios (OR) estimated the link between pain scores and complications. Results: Dexamethasone 8 mg increased IL-10 (b=12.70 (95% CI=8.06– 17.34), P 0.001). Dexamethasone 4 mg and 8 mg decreased the ratio IL-6/IL-10 (b=? 2.60 (? 3.93 to ? 1.26), P 0.001 and b=? 3.59 (? 5.04 to ? 2.13), P 0.001, respectively). We could not show modulatory effects of lidocaine on cytokines. High pain scores were linked to the occurrence of PIRC’s (OR=2.028 (1.134– 3.628), P =0.017). Cytokine levels were not related either to acute pain or PIRC. Conclusion: Dexamethasone modulated the perioperative cytokine response into an anti-inflammatory direction. An overall lidocaine effect was not found. Patients with higher pain scores suffered from more 30-day PIRCs. Cytokine levels were not associated with pain or more postoperative complications, even not with PIRC. Larger studies in breast cancer surgery are needed to confirm these explorative results.
机译:目的:围手术期细胞因子反应的不平衡可能导致急性疼痛和术后并发症。麻醉药物调节这种细胞因子反应,但它们在非主要乳腺癌手术中的作用尚不清楚。在探索性研究中,我们研究了静脉注射利多卡因和地塞米松是否可以调节细胞因子反应抗炎方向。我们还评估了细胞因子水平,疼痛评分和术后并发症之间的相互关系。我们的目标是在乳腺癌手术后开发多峰镇痛方案优化结果。患者和方法:将肿块切除术的48名患者随机分配给安慰剂或利多卡因(1.5mg?kg α1,然后是2mg?kg Δ1?小时< Sup> 1 / sup>)由地塞米松零,4或8毫克补充,得到六组八名患者。白细胞介素(IL)-1β,IL-1RA,IL-6,IL-10水平和疼痛评分在基线和术后4小时。我们评估了30天内发生的术后并发症。我们注意到持续的疼痛和感染作为潜在的免疫相关并发症(PIRC)。我们使用多元回归来解除个体研究药物的影响(由其部分回归系数(B)给出)。赔率比(或)估计疼痛评分和并发症之间的联系。结果:地塞米松8毫克增加IL-10(B = 12.70(95%CI = 8.06-17.34),P <0.001)。地塞米松4毫克和8mg降低了IL-6 / IL-10的比率(B =?2.60(?3.93至α1.26),P <0.001和B =?3.59(?5.04至21.13),P <0.001 )。我们无法显示Lidocaine对细胞因子的调节效果。高疼痛评分与PiRC的发生有关(或= 2.028(1.134-3.628),P = 0.017)。细胞因子水平与急性疼痛或PIRC无关。结论:地塞米松调制围手术期细胞因子反应抗炎方向。没有找到整体利多卡因效应。疼痛评分较高的患者遭受了更多30天的PiRC。细胞因子水平与疼痛或更高的术后并发症无关,甚至没有PIRC。需要在乳腺癌手术中进行更大的研究来确认这些探索结果。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号